(S)-4-Methylene-Pyrrolidine-1,2-Dicarboxylic Acid 1-Tert-Butyl Ester

A primary commercial outlet for (S)-4-Methylene-Pyrrolidine-1,2-Dicarboxylic Acid 1-Tert-Butyl Ester (commonly indexed as Boc-4-methylene-L-proline) is the convergent synthesis of macrocyclic inhibitors targeting the hepatitis C virus NS3/4A serine protease. In the manufacturing route to glecaprevir and voxilaprevir, the enantiopure pyrrolidine scaffold delivers the critical P2 proline mimic with a pendent exocyclic olefin. The terminal alkene serves as the ring-closing metathesis (RCM) anchor, allowing acyclic precursors to be cyclized into a 15- to 18-membered macrocycle under high-dilution conditions. Process-scale RCM is typically conducted at substrate concentrations of 0.005 M to 0.02 M in anhydrous dichloromethane or toluene, using 2^nd generation Hoveyda-Grubbs catalyst at a loading of 2 mol% to 5 mol%. The reaction mass is maintained at 40–60 °C in a glass-lined or Hastelloy C-22 reactor with an inert atmosphere of argon containing <5 ppm oxygen, because the ruthenium alkylidene is sensitive to moisture and air. After in-situ quenching with a metal scavenger—activated carbon Darco G-60 or MP-TMT resin at 10 wt% relative to catalyst—the crude macrocycle is isolated by solvent switch and crystallization from methyl tert-butyl ether/n-heptane. Subsequent global deprotection under acidic conditions exposes the free pyrrolidine amine and the C-terminal carboxylate. Control of the Boc removal step is mandatory: exposure of the 4-methylene-substituted pyrrolidine to trifluoroacetic acid/triisopropylsilane/water (95/2.5/2.5 v/v) at temperatures exceeding 15 °C for longer than 30 minutes initiates exothermic hydration of the exocyclic double bond, forming the inert 4-hydroxymethyl impurity that cannot be purged by short-path distillation. The final drug substance requires enantiomeric purity of >99.5% as determined by chiral SFC on a Chiralpak IG-3 column (3 µm, 4.6×100 mm) with CO₂/methanol (85/15) mobile phase, compliant with Ph. Eur. 2.2.49 and USP <621>. Residual ruthenium is controlled to <10 ppm per USP <233> and monitored by ICP-MS. A summary of residual solvent acceptance criteria under ICH Q3C(R8) is compiled in the following table, listing solvents routinely found when the pyrrolidine building block is supplied as an advanced pharmaceutical intermediate.

Batches shipped under certified CEP or US DMF Type II must be accompanied by a Q-statement confirming that the material has not been exposed to irradiation or ethylene oxide sterilization, and that the single impurity (S)-4-hydroxymethyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester is kept below 0.15% area by HPLC-ELSD. On a commercial scale, isolated yields from the RCM step cluster between 68% and 78% after two crops, with the balance lost to dimeric by-products identified via MALDI-TOF.

What Enables Enantioselective Aldol Catalysis with This Pyrrolidine Scaffold?

The transformation of Boc-4-methylene-L-proline into a family of chiral secondary amine organocatalysts begins with hydroboration-oxidation of the exocyclic alkene. A regioselective borane-tetrahydrofuran complex treatment at -10 °C followed by alkaline hydrogen peroxide (2.5 M NaOH, 30% H₂O₂) installs the primary alcohol at the 4-methylene position without erosion of the C-2 stereocenter. The resultant (2S,4S)-4-(hydroxymethyl)pyrrolidine-1,2-di-tert-butyl ester (or its free acid form) is silylated with tert-butyldimethylsilyl chloride and imidazole in DMF to give the diphenylprolinol silyl ether analogue that has been evaluated in anti-selective cross-aldol reactions between aldehydes and glyoxylates. At a catalyst loading of 10 mol% in acetone at 0 °C, the organocatalyst affords an enantiomeric excess of up to 92% for the condensation of benzaldehyde with diethyl ketomalonate, as extrapolated from structurally analogous 4-substituted prolinol catalysts described in peer-reviewed asymmetric synthesis journals. The configuration of the 4-alkyl substituent exerts a positive steric influence on the iminium transition state, shielding the Re-face of the electrophile. Process chemists must charge the aldehyde substrate via syringe pump over 4–6 hours to prevent catalyst deactivation through irreversible alkylation of the pyrrolidine nitrogen; this observation is consistently reported in early process development batches on 100 mmol scale. After aqueous workup with saturated ammonium chloride, the crude aldol adduct is purified by flash chromatography on silica gel 60 (Merck grade, 230–400 mesh), eluting with ethyl acetate/heptane mixtures. The silyl protecting group remains intact under these conditions, permitting direct re-use of the recovered catalyst precursor. A documented limitation is the sensitivity of the free-base pyrrolidine to oxidative air exposure: storage of the intermediate amino alcohol under argon at -20 °C is essential to avoid N-oxide formation, which manifests as a 1–2% yield loss per day when headspace oxygen exceeds 50 ppm.

Radioligand Precursor Chemistry for PET Imaging Probes

The α,β-unsaturated character of the methylene group is exploited for the installation of tritium or carbon-14 labels into pyrrolidine-containing peptidomimetics destined for receptor occupancy studies. In a typical cold-run validation sequence, the 4-methylene pyrrolidine is dissolved in methanol containing 5% Pd/C (10 wt%, wet basis) and hydrogenated under 1 atm H₂ at ambient temperature, yielding (S)-4-methylpyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester with quantitative conversion. Radiolabeled synthesis replaces hydrogen with tritium gas (5–10 Ci batch charge) in a custom high-vacuum manifold equipped with uranium trap for waste recycle. The specific activity of the reduced product reaches 55–80 Ci/mmol, determined by LC-MS radiochemical detection following the Boc group removal. The labeled amino acid is then elaborated into a tripeptide warhead for covalent binding assays against the 20S proteasome or cathepsin K. Process controls for tritium introduction are governed by the principles of PIC/S Guide PE 009-17 and ISO 16620-5:2017 for biobased carbon content determination. All hot-cell manipulations of the dried palladium catalyst require oxygen-free conditions to avert radiolytic hydrogen peroxide generation in the solvent matrix. Residues of palladium in the final injectable diagnostic must not exceed 10 µg per dose per USP <223>; thus, a solid-phase extraction step on a QuadraSil MP cartridge loaded with 200 mg of scavenger per gram of crude product is implemented immediately after filtration of the catalyst.

Manufacture of Fmoc-4-methylene-L-proline for use as a conformationally restrained residue in Fmoc-based solid-phase peptide synthesis (SPPS) proceeds through the orthogonal deprotection of the 1-tert-butyl ester group and subsequent Nα-Fmoc protection. The Boc-4-methylene-L-proline intermediate is first converted to the corresponding free amino acid ester hydrochloride by treatment with 4M HCl in dioxane at 0–5 °C for 45 minutes, conditions that leave the methylene group intact but necessitate immediate neutralization. After neutralization with triethylamine in dry tetrahydrofuran, Fmoc-OSu (1.05 eq.) is added and the mixture stirred for 12 hours at room temperature. The crude Fmoc-amino acid is isolated by aqueous extraction (pH 3.0, sodium acetate buffer) and recrystallized from ethyl acetate/diisopropyl ether to achieve >96% LC purity. When incorporated into a growing peptide chain on Rink Amide MBHA resin (loading 0.6 mmol/g), the Fmoc-4-methylene building block is coupled using HCTU and N-methylmorpholine in DMF, with double-coupling cycles of 45 minutes each monitored by the Kaiser test. After chain assembly, the resin-bound peptide is exposed to a metathesis catalyst cocktail: Grubbs 2^nd gen catalyst 20 mol% in 1,2-dichloroethane under microwave irradiation at 100 °C for 2 hours to effect a hydrocarbon staple between the 4-methylene residue and an allylglycine residue positioned three amino acids apart. Cleavage from the resin with reagent K (TFA/thioanisole/water/phenol/EDT, 82.5/5/5/5/2.5 v/v) simultaneously removes the side-chain protecting groups while preserving the newly formed macrocycle. The stapled peptide is precipitated and washed in cold diethyl ether, then purified by preparative RP-HPLC on a C18 column (Phenomenex Luna, 10 µm, 250×21.2 mm) using a linear gradient of acetonitrile in 0.1% TFA. A common process failure is the premature metathesis of the resin-bound peptide before complete Fmoc removal, generating an intramolecular dimer that co-elutes with the product; this is mitigated by sequential piperidine deprotection (20% in DMF) with resin washes monitored by conductivity.

When the Exocyclic Olefin Serves as a Metathesis Handle in Macrocyclic Peptide Drugs

The pre-installed methylene group on the pyrrolidine ring enables a streamlined approach to the paritaprevir (ABT-450) P2 subunit. After esterification of the free carboxylic acid to the benzyl ester under standard Steglich conditions (1.1 eq. BnOH, DCC/DMAP in DCM), the sterically hindered exocyclic alkene undergoes a diastereoselective hydroboration with (−)-diisopinocampheylborane [(−)-Ipc₂BH] at -25 °C to install the requisite (R)-hydroxymethyl stereocenter. The organoborane intermediate is oxidized with alkaline peroxide, yielding the alcohol intermediate with a diastereomeric ratio exceeding 20:1 as verified by chiral GC after derivatization with N-methyl-bis(trifluoroacetamide). This alcohol is subjected to a Mitsunobu reaction with 1-naphthalenemethanol, triphenylphosphine, and diisopropyl azodicarboxylate (DIAD) in THF at 0 °C to 25 °C over 16 hours. After aqueous extraction, the crude naphthylmethyl ether is hydrogenolyzed over Pearlman’s catalyst to cleave the benzyl ester, releasing the P2 acid ready for segment condensation. At the production scale, strict control of the DIAD residual level is mandatory: triple washes with 5% aqueous sodium bisulfite followed by charcoal treatment reduce the hydrazodicarboxylate by-product to <0.5%. The free acid’s crystalline form, obtained from hot isopropanol/water, shows a melting endotherm at 158–162 °C by DSC (Mettler Toledo, heating rate 10 K/min, N₂ flow 50 mL/min). When this P2 acid is coupled with the P1-P3 peptide backbone under EDC/HOBt activation in DMF at -10 °C, the isolated yield of paritaprevir precursor exceeds 82% after flash chromatography; the major side product is the 4-exo-methylene positional isomer resulting from an insufficiently stereoselective hydroboration step that must be rigorously controlled below 2.0 area%.

If the Target Is a DPP-4 Inhibitor Analogue, This Chiral Pyrrolidine Provides the Required (S)-Configuration at C-2

The (S)-absolute configuration resident at the pyrrolidine C-2 carbon provides the correct stereochemical input for constructing vildagliptin-type cyanopyrrolidine DPP-4 inhibitors. Catalytic hydrogenation of the methylene group over 10% Pd/C in methanol at 40 psi H₂ furnishes the saturated 4-methylpyrrolidine intermediate without racemization. Following Boc deprotection with 4M HCl/EtOAc, the secondary amine undergoes chloroacetylation with chloroacetyl chloride (1.0 eq.) in dichloromethane containing triethylamine at -5 °C. The resulting chloroacetamide is dehydrated to the corresponding nitrile using trifluoroacetic anhydride and pyridine in THF, with careful monitoring of the internal temperature kept below 15 °C to avoid elimination that forms an unreactive enamine. After aqueous bicarbonate quench and extraction, the crude nitrile is purified via a silica plug, eluting with 30% ethyl acetate in heptane. The isolated yield of the cyanopyrrolidine, a close structural analogue of vildagliptin (2S configuration confirmed by optical rotation), ranges from 55–65% over three steps on a multi-kilo scale. Process safety evaluations performed with differential scanning calorimetry identify an exothermic decomposition onset at 180 °C for the nitrile intermediate, necessitating the use of a reaction calorimeter (Mettler RC1) to validate safe dosing rates for the TFAA/pyridine mixture. The final compound, while an investigational analogue and not a commercial drug product, serves as a reference standard for DPP-4 inhibitor impurity profiling, with identity established by ¹H, ¹³C, and ¹⁹F NMR and a chromatographic purity specification of >98.0% under the ChP HPLC method (Type C18, 5 µm, 4.6×250 mm, mobile phase phosphate buffer pH 3.0/acetonitrile).